Using dual imaging to diagnose oropharyngeal and laryngeal cancer

Application of FDG Combined With FAPI PET Dual Imaging in the Diagnosis and Staging of Oropharyngeal and Laryngeal Cancer

This study is testing if using two types of PET scans together can help doctors better diagnose and stage oropharyngeal and laryngeal cancer in patients who might have it.

Quick facts

• Study type: Observational
• Enrollment: 40 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 1 site (Chongqing, Chongqing)
• Trial ID: NCT06304155 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the diagnostic efficacy of combined FDG and FAPI PET imaging in patients with suspected oropharyngeal and laryngeal cancer. It will involve collecting clinical data and performing various imaging examinations, including CT, MRI, and PET scans, to assess the staging of cancer. The study will analyze the standardized uptake values and other metabolic indicators to improve the accuracy of cancer diagnosis and staging. The research is set to take place from January 2024 to January 2026.

Who should consider this trial

Good fit: Ideal candidates include adults with high clinical suspicion of oropharyngeal or laryngeal cancer who have not yet undergone surgical resection.

Not a fit: Patients who refuse surgery or have already undergone surgical resection will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate diagnosis and staging of oropharyngeal and laryngeal cancers, potentially improving treatment outcomes.

How similar studies have performed: While there is ongoing research in imaging techniques for cancer diagnosis, this specific combination of FDG and FAPI PET imaging is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

1. Patients with high clinical suspicion of oropharyngeal and laryngeal cancer: CT and MR examinations reveal space occupying lesions in the oropharynx and laryngopharynx, with high suspicion of laryngeal cancer;
2. Recently diagnosed patients: patients who have recently been diagnosed with oropharyngeal cancer and laryngeal cancer, have not undergone surgical resection but are willing to undergo surgery;
3. Patients who have been diagnosed with oropharyngeal and laryngeal cancer and have undergone concurrent radiotherapy, chemotherapy, or immunotherapy, and are preparing to undergo preoperative staging in the near future;
4. Patients with high suspicion of oropharyngeal and laryngeal cancer through imaging examination, and later confirmed by pathology as non oropharyngeal or laryngeal cancer;
5. Patient age ≥ 18 years old;
6. The patient voluntarily participates and signs an informed consent form.

Exclusion Criteria:

1. Patients who refuse to undergo surgery;
2. Patients highly suspected of lymphoma or metastasis in clinical or imaging studies;
3. Patients with multiple neck metastases identified through imaging examination that cannot be surgically treated;
4. Patients with malignant tumors in other parts of the body found through imaging examination that cannot be operated on;
5. Pregnancy or lactation period;
6. The imaging quality is poor and cannot be used for diagnosis and evaluation;
7. Patients with contraindications for MR examination.

Where this trial is running

Chongqing, Chongqing

• Department of Nuclear Medicine, Daping Hospital of Army Medical University — Chongqing, Chongqing, China (Recruiting)

Conditions Cancer